Upregulation of miR-9 and Let-7a by nanoencapsulated chrysin in gastric cancer cells
Source abstract
Abstract
Chrysin, as a flavone, has showed cancer chemopreventive activity. The present study utilized the PLGA–PEG–chrysin to evaluate the expression of miR-9 and Let-7a in human gastric cells. The structure of nanoparticles and encapsulated chrysin was evaluated using 1H NMR, FT-IR, and SEM. MTT assay was used for the evaluation of cytotoxicity effect of nanoencapsulated chrysin. Expression levels of miR-9 and Let7-a were studied by real-time PCR. The results demonstrated that chrysin–PLGA–PEG nanoparticles are more effective than pure chrysin in upregulation of miR-9 and Let-7a due to enhanced uptake by cells. Therefore, PLGA–PEG could be a superior carrier for this kind of hydrophobic agent.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Curcumin's Biomedical Applications · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran;
Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
References (25)
Show source-provided references
1. 10.3109/21691401.2015.102963310.3109/21691401.2015.1029633 ↗
2. 10.7314/APJCP.2014.15.20.893110.7314/APJCP.2014.15.20.8931 ↗
3. 10.1016/j.addr.2009.04.01610.1016/j.addr.2009.04.016 ↗
4. 10.1071/EA0813410.1071/EA08134 ↗
5. 10.1016/j.jconrel.2013.01.00110.1016/j.jconrel.2013.01.001 ↗
6. 10.1002/ijc.2921010.1002/ijc.29210 ↗
7. 10.7314/APJCP.2014.15.17.711310.7314/APJCP.2014.15.17.7113 ↗
8. 10.1111/j.1440-1746.2008.05666.x10.1111/j.1440-1746.2008.05666.x ↗
9. 10.1016/j.actbio.2009.08.03610.1016/j.actbio.2009.08.036 ↗
10. 10.1016/j.biomaterials.2014.06.04510.1016/j.biomaterials.2014.06.045 ↗
11. 10.7314/APJCP.2015.16.18.825910.7314/APJCP.2015.16.18.8259 ↗
12. 10.3109/21691401.2015.112961510.3109/21691401.2015.1129615 ↗
13. 10.1038/sj.onc.120928310.1038/sj.onc.1209283 ↗
14. 10.1039/C5RA00018A10.1039/C5RA00018A ↗
15. 10.1002/ijc.2592310.1002/ijc.25923 ↗
16. 10.1016/j.yexmp.2008.12.00410.1016/j.yexmp.2008.12.004 ↗
17. Surendiran A · Indian J Med Res · 2009 · 130 · 689
18. 10.3109/21691401.2014.95510810.3109/21691401.2014.955108 ↗
19. 10.1016/j.addr.2010.03.01110.1016/j.addr.2010.03.011 ↗
20. 10.4161/epi.6.10.1653510.4161/epi.6.10.16535 ↗
21. 10.1016/j.ccr.2006.01.02510.1016/j.ccr.2006.01.025 ↗
22. 10.1093/carcin/bgr03510.1093/carcin/bgr035 ↗
23. 10.1007/s10534-015-9872-610.1007/s10534-015-9872-6 ↗
24. 10.1016/j.toxrep.2014.02.00310.1016/j.toxrep.2014.02.003 ↗
25. 10.1016/j.ejpb.2014.03.01110.1016/j.ejpb.2014.03.011 ↗